BioLineRx Ltd.BLRXEarnings & Financial Report
Nasdaq · biotechnology
BioLineRx Ltd., or BioLine, is a publicly traded drug development company. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange.
BLRX Q2 2025 Key Financial Metrics
Revenue
$304.0K
Gross Profit
$232.0K
Operating Profit
$-2.3M
Net Profit
$-3.9M
Gross Margin
76.3%
Operating Margin
-757.6%
Net Margin
-1296.1%
YoY Growth
-94.4%
EPS
$0.00
Financial Flow
BioLineRx Ltd. Q2 2025 Financial Summary
BioLineRx Ltd. reported revenue of $304.0K (down 94.4% YoY) for Q2 2025, with a net profit of $-3.9M (down 914.0% YoY) (-1296.1% margin). Cost of goods sold was $72.0K, operating expenses totaled $2.5M.
Key Financial Metrics
| Total Revenue | $304.0K |
|---|---|
| Net Profit | $-3.9M |
| Gross Margin | 76.3% |
| Operating Margin | -757.6% |
| Report Period | Q2 2025 |
BioLineRx Ltd. Quarterly Revenue & Net Profit History
BioLineRx Ltd. results over the last 3 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q2 2025 | $304.0K | -94.4% | $-3.9M | -1296.1% |
| Q2 2024 | $5.4M | — | $484.0K | 9.0% |
| Q2 2023 | $0 | — | $-18.5M | N/A |
Income Statement
| Q2 2023 | Q2 2024 | Q2 2025 | |
|---|---|---|---|
| Revenue | $0 | $5.4M | $304000 |
| YoY Growth | N/A | N/A | -94.4% |
Balance Sheet
| Q2 2023 | Q2 2024 | Q2 2025 | |
|---|---|---|---|
| Assets | $58.9M | $64.6M | $43.3M |
| Liabilities | $37.9M | $50.6M | $23.2M |
| Equity | $21.1M | $13.9M | $20.1M |
Cash Flow
| Q2 2023 | Q2 2024 | Q2 2025 | |
|---|---|---|---|
| Operating CF | $-17.7M | $-25.4M | $-2.8M |